SCHEMBL75688

SCHEMBL75688

CC(C)c1ccn[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5261057 0.80
SCHEMBL2555709 0.80
SCHEMBL7981606 0.80
SCHEMBL19814435 0.80
SCHEMBL9963438 0.80 KDM4E (0.48)
Hydrochloric Acid SCHEMBL23610812 0.78 KDM4E (0.47)
SCHEMBL13104629 0.77
SCHEMBL14464033 0.77
SCHEMBL440680 0.77 KDM4E (0.46)
SCHEMBL18477665 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 905 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4707276-A2 MALT1 MODULATORS AND USES THEREOF Rarefied Biosciences, Inc. (US) 2026-03-11 EP disclosed
EP-4499611-B1 MALT1 MODULATORS AND USES THEREOF RAREFIED BIOSCIENCES INC (US) 2026-02-18 EP disclosed
WO-2025226510-A1 LPAR1 INHIBITORS ABBVIE INC. (US) 2025-10-30 WO disclosed
US-20250326738-A1 MALT1 Modulators and Uses Thereof RAREFIED BIOSCIENCES, INC. (US) 2025-10-23 US disclosed
US-20250276966-A1 Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives PFIZER (US) 2025-09-04 US disclosed
US-20250129044-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2025-04-24 US disclosed
US-20250122183-A1 Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives PFIZER (US) 2025-04-17 US disclosed
EP-4499611-A1 MALT1 MODULATORS AND USES THEREOF Rarefied Biosciences, Inc. (US) 2025-02-05 EP disclosed
EP-4471027-A1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF ONO Pharmaceutical Co., Ltd. (JP) 2024-12-04 EP disclosed
CN-112469407-B Methods for treating postprandial hypoglycemia 阿沃林特有限公司 2024-10-01 CN disclosed
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 US disclosed
US-20070082906-A1 Inhibitors of akt activity MERCK SHARP & DOHME CORP. 2007-04-12 US disclosed
US-7189721-B2 Bicyclic protein kinase inhibitors SUGEN INC. (US) 2007-03-13 US disclosed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 US disclosed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US disclosed
US-20070015748-A1 Kinase Inhibitors ALLERGAN, INC. 2007-01-18 US disclosed
US-7163932-B2 Aryldifluoromethylphosphonic acids for treatment of diabetes MERCK FROSST CANADA & CO. (CA) 2007-01-16 US disclosed
CN-1744916-A Preventive or remedy for diseases caused by hyperglycemia KISSEI PHARMACEUTICAL (JP) 2006-03-08 CN disclosed
CN-1688597-A Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof KISSEI PHARMACEUTICAL COMPANY (JP) 2005-10-26 CN disclosed
CN-1688596-A Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof KISSEI PHARMACEUTICAL COMPANY (JP) 2005-10-26 CN disclosed